The present Invention relates to a Pharmaceutical composition comprising an FXR agonist, at least an agonist of PPAR alpha,Agonist of PPAR Delta agonist and \/ or dual PPAR alpha and Delta and \/ or optionally one or more pharmaceutically acceptable vehicle.The Agonist of PPAR alpha is a fibrate May comobenzafibrato, clinofibrate nicofibrate, among others The Agonist of PPAR Delta is acid, 4 - [({{4 - methyl - 2 - [4 - (trifluoromethyl) phenyl] - 1,3 - 5 - Methyl thiazole il}) sulfanyl] - 2 - metilfenoxi} acetic acid, among others.Said composition is useful for the Treatment or prevention of a disease or condition mediated FXR, such as primary biliary cirrhosis (PBC), Primary sclerosing cholangitis (PSC),Portal hypertension, diarrhea by Bile acids, NAFLD (non-alcoholic fatty liver disease), Nash (nonalcoholic steatohepatitis induced by alcohol), and other chronic Liver Diseases.Also, the combination of the present Invention is useful for the Treatment or prevention of diseases associated with elevated lipid levels and liver EnzymesLa presente invencion se relaciona con una composicion farmaceutica que comprende un agonista de FXR, por lo menos un agonista de PPAR-alfa, agonista de PPAR-delta y/o agonista dual de PPAR-alfa y delta y/o opcionalmente uno o mas vehiculos farmaceuticamente aceptables. El agonista de PPAR-alfa es un fibrato tal comobenzafibrato, clinofibrato, nicofibrato, entre otros el agonista de PPAR-delta es acido {4-[({4-metil-2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}metil)sulfanil]-2-metilfenoxi}acetico, entre otros. Dicha composicion es util para el tratamiento o prevencion de una enfermedad o afeccion mediada por FXR, tal como cirrosis biliar primaria (PBC), colangitis esclerosante primaria (PSC), hipertension portal, diarrea por acidos biliares, NAFLD (enfermedad de higado graso no alcoholica), NASH (esteatohepatitis no inducida por alcohol), y otras enfermedades hepaticas cronicas. Asi tambien, la combinacion de la presente invencion es util
